Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Accumulated Expenses (2017 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Other Accumulated Expenses for 9 consecutive years, with $840000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 101.44% year-over-year to $840000.0, compared with a TTM value of $840000.0 through Dec 2025, up 101.44%, and an annual FY2025 reading of $840000.0, up 101.44% over the prior year.
  • Other Accumulated Expenses was $840000.0 for Q4 2025 at Catalyst Pharmaceuticals, roughly flat from $842000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.2 million in Q1 2025 and bottomed at $372000.0 in Q2 2024.
  • Average Other Accumulated Expenses over 3 years is $794625.0, with a median of $606000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses dropped 10.32% in 2024, then skyrocketed 101.44% in 2025.
  • Year by year, Other Accumulated Expenses stood at $465000.0 in 2023, then fell by 10.32% to $417000.0 in 2024, then surged by 101.44% to $840000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for CPRX at $840000.0 in Q4 2025, $842000.0 in Q3 2025, and $747000.0 in Q2 2025.